<DOC>
	<DOC>NCT02857868</DOC>
	<brief_summary>The main purpose of this study is to evaluate the effect of varying degrees of impaired hepatic function (by Child-Pugh classification) on the pharmacokinetics (PK) of ABL001 after a single oral dose.</brief_summary>
	<brief_title>A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Key Inclusion criteria: Body mass index of 1836 kg/m2, with body weight 50 kg and no more than 120 kg Vital signs (after at least 3 minutes rest in the supine position) within the following ranges (inclusive): Oral body temperature between 35.0 °C 37.5 °C (95.099.5°F) Systolic BP ≥90 mmHg and ≤140 mmHg Diastolic BP ≥60 mmHg and ≤90 mmHg for healthy subjects and 50100 mmHg for subjects with impaired hepatic function (groups 24) Pulse Rate: ≥50 and ≤90 bpm for healthy subjects (group 1) and ≥50 and ≤100 bpm for subjects with impaired hepatic function (groups 24) Healthy subjects with no clinically significant abnormalities as determined by past medical history, physical examination, vital signs, ECG, and clinical laboratory test Subjects with ChildPugh Clinical Assessment Score as calculated per the ChildPugh classification Key Presence of clinically significant ECG abnormalities or a family history or presence of prolonged QTinterval syndrome History of cardiac disease Sexually active males must use a condom during intercourse while taking the drug and for 7 days after stopping Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs Administration of strong or moderate CYP3A4 inhibitors or inducers (including St John's wort) within 14 days prior to dosing Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatic Impairment</keyword>
	<keyword>ABL001</keyword>
	<keyword>Child-Pugh</keyword>
	<keyword>healthy subjects with normal hepatic function</keyword>
</DOC>